A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Nuvectis Pharma, Inc.
University of Pennsylvania
Carisma Therapeutics Inc
Advaxis, Inc.
Adaptimmune
KitovPharma
National Institutes of Health Clinical Center (CC)
Santa Maria Biotherapeutics
University of Miami
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)